Pulmonary arterial hypertension

the long version

Pulmonary arterial hypertension (PAH) is a rare condition; yet this very rarity can be a disadvantage when it comes to treatment, making PAH difficult to diagnose, and resulting in suboptimal patient care. Furthermore, the global burden of PAH remains poorly understood and largely underestimated, as PAH commonly presents as a comorbidity with such conditions as systemic sclerosis, COPD, idiopathic pulmonary fibrosis and left-heart dysfunction. However, in recent years there has been significant investment in developing new therapies for PAH, and treatment for this previously neglected disease.